Cargando…
Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available...
Autores principales: | Sun, Rui-Fang, Yu, Qian-Qian, Young, Ken H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Medical Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938286/ https://www.ncbi.nlm.nih.gov/pubmed/29756121 http://dx.doi.org/10.1016/j.cdtm.2018.02.001 |
Ejemplares similares
-
Editorial: The notch signaling pathway in lymphoid malignancies
por: Fais, Franco, et al.
Publicado: (2023) -
The EHA Research Roadmap: Malignant Lymphoid Diseases
por: Dreyling, Martin, et al.
Publicado: (2022) -
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies
por: Lodewijckx, Inge, et al.
Publicado: (2021) -
The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies
por: Sujobert, Pierre, et al.
Publicado: (2018) -
Utilizing journal club to facilitate critical thinking in pre-clinical medical students
por: Lucia, Victoria C., et al.
Publicado: (2018)